Details: pack, label wording, sources, registration
Metabolase, Solution
solution for injection
vetman assessment
vetman’s 10-point assessment brings together a product’s regulatory credibility, clinical efficacy, safety and practicality. Cost-effectiveness is assessed only when reliable data are available. It is informational and does not replace a veterinarian’s clinical judgment for an individual patient.
Dog
Adjunctive supportive use during physical stress and convalescence
4.3/10
Weak evidence support
Details →
vetman assessment
Metabolase
×
solution for injection
Assessed clinical scope Dog · Adjunctive supportive use during physical stress and convalescence · IV,SC
Care setting Veterinarian-directed clinic treatment after defining the underlying diagnosis and a measurable treatment goal
vetman score
4.3/10
Weak evidence support
Evidence confidence: Low
Georgia: Yes, veterinary · № 000353 · Verified on 15 Oct 2026
A transparent authorised supportive injectable with a verifiable dog regimen, but weak evidence for clinically meaningful benefit across its broad claims and substantial twice-daily volume burden.
Regulatory and scientific credibility 6.5/10
Exact identity, composition, regimen and current Georgian/EU authorisations are verifiable, but no public assessment dossier or independent exact-formulation outcome evidence was located.
Clinical efficacy 2.0/10
No controlled exact-product dog/cat outcome study was located. Broad label claims are mainly mechanistic; oral single-ingredient studies in different settings cannot validate this multi-ingredient injectable.
Safety and tolerability 5.0/10
The exact label reports no specified adverse effects or contraindications and permits pregnancy/lactation, but gives no quantified dog/cat safety incidence, comparative tolerance study or organ-disease limits.
Clinical practicality 3.0/10
Twice-daily IV/SC treatment is technically straightforward in clinic, but 2–4 ml/kg produces large repeated volumes, staff/restraint/site burden and an undefined course duration.
Full-course cost-effectiveness -
No verified current Georgian patient-adjusted course price or evidence-based course duration was available; cost was excluded.
Important safety and use flags
This score covers the broad labelled adjunctive role during physical stress/convalescence; it does not establish treatment of a specific disease, “detoxification”, organ repair or improved survival. Use only after diagnosing and treating the underlying condition; do not let a supportive metabolic injection delay fluids, nutrition, analgesia, antimicrobials, antidotes or other indicated disease-specific care. No controlled exact-product dog/cat clinical-outcome study was located. Ingredient mechanisms and oral L-carnitine studies are indirect and cannot be added together as proof for this injectable mixture. Dog label dose is 2–4 ml/kg twice daily IV or SC. Cat label dose is 2–4 ml/kg twice daily SC only, divided among multiple injection sites; do not transfer the canine IV route to cats. The repeated volume is substantial: 20–40 ml per dose for a 10 kg dog and 8–16 ml per dose for a 4 kg cat. Plan restraint, asepsis, site rotation, tissue capacity and monitoring before administration. The label does not define a course duration or response endpoint. Set a measurable goal and reassess promptly; do not continue repeated injections by habit when objective benefit is absent. Although the label lists no adverse effects or contraindications, quantified dog/cat safety data are not published. Monitor injection sites, pain, swelling, hypersensitivity and clinical deterioration. Assess hydration, cardiovascular/renal status and tolerance of the administered volume. Large repeated SC or IV volumes are not a substitute for an individual fluid plan. Do not mix with another injectable or add to an infusion bag unless physical/chemical compatibility is specifically verified. Use aseptic technique and inspect the solution/container. Record first opening and discard after 28 days. Cost-effectiveness is not scored because a current Georgian course price and evidence-based course duration were unavailable. Assessment sources +
Close
Cat
Adjunctive supportive use during physical stress and convalescence
4.1/10
Weak evidence support
Details →
vetman assessment
Metabolase
×
solution for injection
Assessed clinical scope Cat · Adjunctive supportive use during physical stress and convalescence · Subcutaneous
Care setting Veterinarian-directed clinic treatment after defining the underlying diagnosis and a measurable treatment goal
vetman score
4.1/10
Weak evidence support
Evidence confidence: Low
Georgia: Yes, veterinary · № 000353 · Verified on 15 Oct 2026
A transparent authorised supportive injectable with a verifiable cat regimen, but weak evidence for clinically meaningful benefit and a particularly heavy twice-daily multi-site SC volume burden.
Regulatory and scientific credibility 6.5/10
Exact identity, composition, regimen and current Georgian/EU authorisations are verifiable, but no public assessment dossier or independent exact-formulation outcome evidence was located.
Clinical efficacy 2.0/10
No controlled exact-product dog/cat outcome study was located. Broad label claims are mainly mechanistic; oral single-ingredient studies in different settings cannot validate this multi-ingredient injectable.
Safety and tolerability 5.0/10
The exact label reports no specified adverse effects or contraindications and permits pregnancy/lactation, but gives no quantified dog/cat safety incidence, comparative tolerance study or organ-disease limits.
Clinical practicality 2.0/10
The 2–4 ml/kg SC dose twice daily equals 8–16 ml per dose in a 4 kg cat and must be split among sites, creating major restraint, tissue-volume and repeat-visit burden with no defined course duration.
Full-course cost-effectiveness -
No verified current Georgian patient-adjusted course price or evidence-based course duration was available; cost was excluded.
Important safety and use flags
This score covers the broad labelled adjunctive role during physical stress/convalescence; it does not establish treatment of a specific disease, “detoxification”, organ repair or improved survival. Use only after diagnosing and treating the underlying condition; do not let a supportive metabolic injection delay fluids, nutrition, analgesia, antimicrobials, antidotes or other indicated disease-specific care. No controlled exact-product dog/cat clinical-outcome study was located. Ingredient mechanisms and oral L-carnitine studies are indirect and cannot be added together as proof for this injectable mixture. Dog label dose is 2–4 ml/kg twice daily IV or SC. Cat label dose is 2–4 ml/kg twice daily SC only, divided among multiple injection sites; do not transfer the canine IV route to cats. The repeated volume is substantial: 20–40 ml per dose for a 10 kg dog and 8–16 ml per dose for a 4 kg cat. Plan restraint, asepsis, site rotation, tissue capacity and monitoring before administration. The label does not define a course duration or response endpoint. Set a measurable goal and reassess promptly; do not continue repeated injections by habit when objective benefit is absent. Although the label lists no adverse effects or contraindications, quantified dog/cat safety data are not published. Monitor injection sites, pain, swelling, hypersensitivity and clinical deterioration. Assess hydration, cardiovascular/renal status and tolerance of the administered volume. Large repeated SC or IV volumes are not a substitute for an individual fluid plan. Do not mix with another injectable or add to an infusion bag unless physical/chemical compatibility is specifically verified. Use aseptic technique and inspect the solution/container. Record first opening and discard after 28 days. Cost-effectiveness is not scored because a current Georgian course price and evidence-based course duration were unavailable. Assessment sources +
Close
Administration route
Intravenous, Subcutaneous
Manufacturer (register)
FATRO S.p.A., Italy
Manufacturer and country as in the veterinary medicines register (National Food Agency), row 852, 19 Oct 2026.
Registration
Georgia
Yes, veterinary
In force until 21 Jun 2028
Veterinary (National Food Agency)
In the register: მეტაბოლაზი
№ 000353
Verified on: 15 Oct 2026
EU
Yes, veterinary
UK
Not confirmed
US
Not confirmed
Controlled in Georgia
Unknown
Information not fully verified
Label regimen for adjunctive supportive use during physical stress/convalescence: dog 2–4 ml/kg twice daily IV or SC; cat 2–4 ml/kg twice daily SC, divided among multiple injection sites. The label does not define an evidence-based course duration. Do not extrapolate this broad metabolic-support wording to disease modification, hepatic/renal detoxification or improved survival.
Dose Species Weight Route Frequency Source
2–4 ml/kg
Exact label: give SC twice daily and divide the dose among multiple injection sites.
Cat
Any weight
Subcutaneous
twice daily
Metabolase EU leaflet
Official product label (SPC)
Approved by a medicines regulator as part of the product's authorisation. It applies to that product as authorised there.
Metabolase solution for injection - current Italian package leaflet
EU Union Product Database, 2022
2–4 ml/kg
Exact label: give IV twice daily.
Dog
Any weight
Intravenous
twice daily
Metabolase EU leaflet
Official product label (SPC)
Approved by a medicines regulator as part of the product's authorisation. It applies to that product as authorised there.
Metabolase solution for injection - current Italian package leaflet
EU Union Product Database, 2022
2–4 ml/kg
Exact label: give SC twice daily.
Dog
Any weight
Subcutaneous
twice daily
Metabolase EU leaflet
Official product label (SPC)
Approved by a medicines regulator as part of the product's authorisation. It applies to that product as authorised there.
Metabolase solution for injection - current Italian package leaflet
EU Union Product Database, 2022
